Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age

Li, Christopher I.; Daling, Janet R.; Haugen, Kara L.; Tang, Mei Tzu C; Porter, Peggy L.; Malone, Kathleen E.

doi:10.1007/s10549-014-2960-4

Cited by 25 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to IDC tumors, ILC tumors are more commonly ER+ [20] which offers a potential mechanism for the stronger association with ILC cancers. This is further supported by evidence from previous studies showing an association between postmenopausal hormone therapy and risk of ILC [21, 22]. …”

Section: Discussionsupporting

confidence: 85%

Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years

et al. 2017

Self Cite

View full text Add to dashboard Cite

Previous studies suggest that alcohol consumption and risk of breast cancer may differ by histologic subtype and hormone receptor status, though results are not entirely consistent. In this population-based case-control study, we evaluated the association between alcohol consumption and risk of invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and invasive ductal-lobular carcinoma (IDLC) overall and by estrogen receptor (ER) status, among women aged 55–74 years of age. Using polytomous regression, associations between current alcohol consumption, overall and by type of alcohol, and breast cancer risk were evaluated in 891 controls and 905 IDC, 567 ILC, 489 IDLC cases. Current alcohol use was moderately associated with risk of ILC (odds ratio=1.25, 95% confidence interval: 0.99, 1.58) with a positive dose-response relationship based on average number of drinks per week consumed (Ptrend=0.0005). When further stratified by ER status, alcohol use was positively associated with risk of ER+ ILC (Ptrend=0.002) and ER+ IDC (Ptrend=0.02), but inversely associated with risk of ER− IDC (Ptrend=0.01). No association between alcohol and risk of IDLC tumors was observed. While the link between alcohol consumption and breast cancer risk is well established, our results suggest that the increased risk associated with alcohol is largely limited to ER+ ILC and ER+ IDC. Thus, avoiding or moderating alcohol consumption may be one way that women can lower their risks of these forms of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 85%

Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…As already published by several authors , we observe that the risk of the second most common type of breast cancer, invasive lobular carcinoma is more strongly associated with HT use than the risk of other nonlobular invasive subtypes; HR = 3.10 (2.51–3.81) versus 1.94 (1.78–2.12). For DCIS, published data have varied.…”

Section: Discussionsupporting

confidence: 73%

Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register‐based cohort study

Suhrke

Zahl

2015

Cancer Medicine

View full text Add to dashboard Cite

In Norway, the breast cancer incidence increased by 50% in the 1990s, during a period with initiation of mammography screening as well as a fourfold increase in use of menopausal hormone therapy (HT). After 2002, the HT use has dropped substantially; however, the breast cancer incidence has declined only marginally. How much mammography screening contributed to the breast cancer incidence increase in the 1990s compared with HT use and specifically different types of HT use, has thus been discussed. Whether HT affects the incidence of subtypes of breast cancer differently has also been questioned. We have linked individual data from several national registries from 2004 to 2009 on 449,717 women aged 50–65 years. 4597 cases of invasive cancer and 681 cases of ductal carcinoma in situ (DCIS) were included in the analysis. We used Cox regression to estimate hazard ratio (HR) as a measure of the relative risk of breast cancer associated with use of HT. The HRs associated with prescriptions of HT for more than 1 year were 2.06 (1.90–2.24) for estrogen and progesterone combinations, 1.03 (0.85–1.25) for systemic estrogens, and 1.23 (1.01–1.51) for tibolone. Invasive lobular carcinoma was more strongly associated with use of estrogen and progesterone combinations, HR = 3.10 (2.51–3.81), than nonlobular carcinoma, HR = 1.94 (1.78–2.12). The corresponding value for DCIS was 1.61 (1.28–2.02). We estimated the population attributable fraction to 8.2%, corresponding to 90 breast cancer cases in 2006 indicating that HT use still caused a major number of breast cancer cases.

show abstract

“…The decline in LCIS incidence among women ages 50 to 69 years is notable, because studies have shown stronger associations between MHT use and ILC than between MHT use and IDC. 82 Treatment Patterns for DCIS and LCIS Figure 3 illustrates surgical treatment patterns for women who were diagnosed with a first primary DCIS or LCIS in the United States from 2007 to 2011. Among women of all ages who were treated for DCIS, BCS was the most common surgical treatment (69%), followed by unilateral mastectomy (19%), bilateral mastectomy (8%), and no surgery (4%).…”

Section: Breast Carcinoma In Situ Incidence Trendsmentioning

confidence: 99%

Cancer statistics: Breast cancer in situ

Ward

DeSantis

Lin

et al. 2015

CA A Cancer J Clinicians

195

142

View full text Add to dashboard Cite

An estimated 60,290 new cases of breast carcinoma in situ are expected to be diagnosed in 2015, and approximately 1 in 33 women is likely to receive an in situ breast cancer diagnosis in her lifetime. Although in situ breast cancers are relatively common, their clinical significance and optimal treatment are topics of uncertainty and concern for both patients and clinicians. In this article, the American Cancer Society provides information about occurrence and treatment patterns for the 2 major subtypes of in situ breast cancer in the United States-ductal carcinoma in situ and lobular carcinoma in situ-using data from the North American Association of Central Cancer Registries and the 13 oldest Surveillance, Epidemiology, and End Results registries. The authors also present an overview of in situ breast cancer detection, treatment, risk factors, and prevention and discuss research needs and initiatives.

show abstract

Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age

Cited by 25 publications

References 25 publications

Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years

Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years

Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register‐based cohort study

Cancer statistics: Breast cancer in situ

Contact Info

Product

Resources

About